Trastuzumab was recognized by Fc receptors of the innate immune system cells, including natural killer cells, antigen presenting cells and effector immune cells, once it bound to HER2 on cancer cell membranes, and this reduced the bounding of trastuzumab with cancer cell41,42. Here, ERBB2 is linked to cancer.